Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy
Publication
, Conference
Ghobadi, A; Baiocchi, R; Beitinjaneh, AM; Chaganti, S; Choquet, S; Dierickx, D; Dinavahi, R; Duan, X; Gamelin, L; Mahadeo, KM; Mehta, A ...
Published in: Blood
November 5, 2024
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
70 / 70
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ghobadi, A., Baiocchi, R., Beitinjaneh, A. M., Chaganti, S., Choquet, S., Dierickx, D., … Prockop, S. E. (2024). Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy. In Blood (Vol. 144, pp. 70–70). American Society of Hematology. https://doi.org/10.1182/blood-2024-198159
Ghobadi, Armin, Robert Baiocchi, Amer M. Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, et al. “Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy.” In Blood, 144:70–70. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-198159.
Ghobadi A, Baiocchi R, Beitinjaneh AM, Chaganti S, Choquet S, Dierickx D, et al. Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy. In: Blood. American Society of Hematology; 2024. p. 70–70.
Ghobadi, Armin, et al. “Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 70–70. Crossref, doi:10.1182/blood-2024-198159.
Ghobadi A, Baiocchi R, Beitinjaneh AM, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Mahadeo KM, Mehta A, Nikiforow S, Reshef R, Roye S, Vedovato J-C, Prockop SE. Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy. Blood. American Society of Hematology; 2024. p. 70–70.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
70 / 70
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology